NeuroBliss started in a small makeshift lab in Iron Alley, built by a self-taught scientist named Hans Yarr. Surrounded by scavenged equipment, broken medical devices, and discarded corporate technology, Hans spent his nights studying nanotechnology and biohacking. He believed there had to be a better way to influence the brain than the drugs already on the market. Most substances worked by interacting with receptors throughout the body, often causing unwanted side effects along with their intended effects. Hans wanted something more precise. After years of experimenting with whatever materials he could get his hands on, he developed Formula 207, the first version of what would eventually become NeuroBliss.
The idea behind NeuroBliss was simple but revolutionary. Instead of flooding the brain with chemicals and hoping for the desired response, Hans designed microscopic particles called neural nanites that could seek out specific neural pathways. Their specially engineered coatings allowed them to pass through the blood-brain barrier, while their molecular guidance systems helped direct them toward targeted neurons. Once there, they released tiny amounts of synthetic neuromodulators designed to influence mood, focus, and pleasure. In theory, this meant users could experience intense euphoria and heightened awareness without the anxiety, confusion, and physical discomfort associated with conventional drugs. The nanites could even respond to local chemical signals, adjusting their activity to keep the effects within an ideal range. It was an ambitious idea, and Hans believed he had finally found a way to make it work. What he could not predict was how others would use his invention.
When a small group of local investors learned about Hans’s discovery, they saw an opportunity to bring something new to Iron Alley. They funded early production and distributed NeuroBliss to residents as an experimental drug. Word spread quickly. People reported feeling happier, sharper, and more alive than they had in years. For a district where exhaustion and despair were part of everyday life, the drug offered something people desperately wanted. Its success eventually attracted NeuroCorp, which approached Hans and bought the rights to his formula. With corporate resources behind it, NeuroBliss spread far beyond Iron Alley, showing up in convenience stores, bars, restaurants, and vending kiosks across the city. What had started in a cramped neighborhood lab was suddenly everywhere, and Hans’s little experiment had become a multimillion-credit industry.
NeuroBliss became just as recognizable for its appearance as its effects. Its distinctive blue and violet glow came from the nanites themselves, whose engineered surfaces scattered and refracted light while producing a faint luminescence. Under the city’s neon signs, the drug almost seemed to glow from within. But as its popularity grew, underground dealers began producing their own modified versions, pushing the formula beyond what Hans had originally intended. Some variants delivered stronger highs, while others extended the effects for hours. Many were made with unstable nanites or altered chemical payloads that sacrificed safety for potency. Reports of neurological damage, severe reactions, and users who never fully recovered began to surface. Hans had wanted to give people a little more control over their own minds. Instead, his invention had become a lucrative business, and not everyone selling it cared what happened to the people taking it.